Clinical Trial Update: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating inhaled treprostinil for idiopathic pulmonary fibrosis and interstitial lung disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease

Drugs mentioned

• Tyvaso (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Status: COMPLETED